10,381
Participants
Start Date
November 3, 2021
Primary Completion Date
February 18, 2022
Study Completion Date
April 14, 2023
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
Shifa International Hospitals, Islamabad
Central Hospital Gujranwala, Gujranwala
Al Khidmat Foundation - Surraya Azeem Waqf Hospital, Lahore
Avicenna Dental College, Lahore
Central Park Medical College and Hospital, Lahore
Aga Khan University Hospital, Karachi
Dow University Hospital, Karachi
Sindh Infectious Diseases Hospital & Research Center, Karachi
Sarawak General Hospital, Kuching
Sunway Medical Centre Velocity (SMCV) Cheras, Kuala Lumpur
Hospital Pakar Sultanah Fatimah, Muar town
Sunway Medical Centre (SunMed), Petaling Jaya
Hospital Pulau Pinang, Pulau Pinang
Klinik Kesihatan Seremban 2, Seremban
Seri Manjung Hospital, Seri Manjung
Hospital Sibu, Sibu
Hospital Sultan Abdul Halim, Sungai Petani
Hospital Taiping, Taiping
Lead Sponsor
Livzon Pharmaceutical Group Inc.
INDUSTRY